In the second phase, the extended cohort of 178 tumour biopsies and the deep sequencing coverage enabled us to detect not only rare subclonal mutations, especially in TP53 and mucin coding genes MUC6, MUC16, and MUC3A, but also early genomic alterations such as PBRM1 and VHL with enough statistical power. This evidence concerns the gene PBRM1 and neoplasm.